Cost-effectiveness of annual microalbuminuria screening in Thai diabetics

Asian Biomedicine

Volumn 8, Issue 3, 2014, Pages 371-379

  Srisubat, Attasit ^a   Sriratanaban, Jiruth ^a   Ngamkiatphaisan, Sureerat ^b   Tungsanga, Kriang ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

Author keywords

Cost effectiveness; Diabetes; Healthcare system; Microalbuminuria; Screenin

Indexed keywords

CREATININE;

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; END STAGE RENAL DISEASE; HEMODIALYSIS; HUMAN; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERITONEAL DIALYSIS; PROBABILITY; QUALITY OF LIFE; RISK ASSESSMENT; SCREENING; THAILAND; URINALYSIS;

EID: 84908025227     PISSN: 19057415     EISSN: 1875855X     Source Type: Journal    
DOI: 10.5372/1905-7415.0803.301     Document Type: Article

References (36)

1. Klein R, Klein BE, Moss S, DeMets DL. Proteinuria in diabetes. Arch Intern Med. 1988; 148:181-6.
2. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998; 128:982-8.
3. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006; 4:CD006257.
4. Sakthong P, Tangphao O, Eiam-ong S, Kamolratanakul P, Supakankunti S, Himathongkam T, et al. Costeffectiveness of using angiotensin-converting enzyme inhibitors to slow nephropathy in normotensive patients with diabetes type II and microalbuminuria. Nephrology. 2001; 6:71-7.
5. Chadban S, Howell M, Twigg S, Thomas M, Jerums G, Cass A, et al. The CARI guidelines. Costeffectiveness and socioeconomic implications of prevention and management of chronic kidney disease in type 2 diabetes. Nephrology. 2010; 15(Suppl 1): S195-S203.
6. Rippin JD, Barnett AH, Bain SC. Cost-effective strategies in the prevention of diabetic nephropathy. Pharmacoeconomics. 2004; 22:9-28.
7. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003; 63:225-32.
8. Krairittichai U, Potisat S, Jongsareejit A, Sattaputh C. Accuracy of urine dipstick test for microalbuminuria in type 2 diabetes mellitus patients. J Med Assoc Thai. 2011; 94 Suppl 2:S6-10.
9. Lepore G, Maglio ML, Nosari I, Dodesini AR, Trevisan R. Cost-effectiveness of two screening programs for microalbuminuria in type 2 diabetes. Diabetes Care. 2002; 25:2103-4.
10. United Nation Thailand. Thailand Info [internet] 2010 [cited 2011 Jun 18]. Available from: http://www.un.or.th/thailand.
11. National Health Security Office. Annual report of Thai Universal Health Coverage Scheme 2009. Bangkok: Sahamitr Printing and Publishing; 2010.
12. Zhang AH, Cheng LT, Zhu N, Sun LH, Wang T. Comparison of quality of life and causes of hospitalization between hemodialysis and peritoneal dialysis patients in China. Health Qual Life Outcomes. 2007; 5:49.
13. Remuzzi G, Ruggenenti P, Perna A, Dimitrov BD, de Zeeuw D, Hille DA, et al. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: A post hoc analysis of the RENAAL trial results. J Am Soc Nephrol. 2004; 15:3117-25.
14. McIntosh A, Hutchinson A, Marshall S, Barnes D, Brown V, Hopper S, et al. Clinical guidelines and evidence review for type 2 diabetes. Renal disease: Prevention and early management. Sheffield: ScHARR, University of Sheffield; 2002.
15. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998; 13:397-409.
16. Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med. 2005; 143:89-99.
17. Ministry of Public Health, Thailand. Public health statistics 2010 [Internet] 2010 [cited 2011 Jun 18]. Available from: http://bps.ops.moph.go.th/Healthinformation/statistic53/statistic53.pdf.
18. Groop PH, Thomas MC, Moran JL, Wadn J, Thorn LM, Mkinen VP, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes. 2009; 58:1651-8.
19. Pratipanawatr T, Rawdaree P, Chetthakul T, Bunnag P, Ngarmukos C, Benjasuratwong Y, et al. Thailand Diabetic Registry cohort: Predicting death in Thai diabetic patients and causes of death. J Med Assoc Thai. 2010; 93(Suppl 3):S12-S20.
20. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
21. Tongsiri S, Cairns J. Estimating population-based values for EQ-5D health states in Thailand. Value Health. 2011; 14:1142-5.
22. World Health Organization. Choosing interventions that are cost-effective (WHO-CHOICE): costeffectiveness thresholds [internet] 2005 [cited 2011 Aug 24]. Available from: http://www.who.int/choice/costs/CER-levels/en/index.html.
23. The World Bank. GDP per capita (current US$) [internet] 2011 [cited 2012 Aug 24]. Available from: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD.
24. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006; 17:2937-44.
25. Thaweethamcharoen T, Sakulbumrungsil R, Vasuvattakul S, Nopmaneejumruslers C. Comparison of SF-6D, EQ-5D and VAS in hemodialysis Thai patients. Value Health. 2010; 13:A567.
26. Liem YS, Bosch JL, Hunink MG. Preference-based quality of life of patients on renal replacement therapy: A systematic review and meta-analysis. Value Health. 2008; 11:733-41.
27. Thavorncharoensap M, Teerawattananon Y, Natanant S, Werayingyong P, Yothasamut J, Putchong C, et al. Assessing a societal value for a ceiling threshold in Thailand. Nonthaburi, Thailand: Health Intervention and Technology Assessment Program; 2009.
28. Kessler R, Keusch G, Szucs TD, Wittenborn JS, Hoerger TJ, Brugger U, et al. Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland. Swiss Med Wkly. 2012; 142: W13508.
29. Siegel JE, Krolewski AS, Warram JH, Weinstein MC. Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus. J Am Soc Nephrol. 1992; 3(4 Suppl): S111-9.
30. Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: An economic evaluation. BMJ. 1995; 311:1595-9.
31. Palmer AJ, Valentine WJ, Chen R, Mehin N, Gabriel S, Bregman B, et al. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant. 2008; 23:1216-23.
32. Palmer AJ, Chen R, Valentine WJ, Roze S, Bregman B, Mehin N, et al. Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes. Diabetes Metab. 2006; 32:69-76.
33. Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: A cost-effectiveness analysis. JAMA. 2003; 290:3101-14.
34. Howard K, White S, Salkeld G, McDonald S, Craig JC, Chadban S, et al. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: A modeled analysis. Value Health. 2010; 13:196-208.
35. Kiberd BA, Jindal KK. Should all Pima Indians with type 2 diabetes mellitus be prescribed routine angiotensin-converting enzyme inhibition therapy to prevent renal failure? Mayo Clin Proc. 1999; 74:559-64.
36. Golan L, Birkmeyer JD, Welch HG. The costeffectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med. 1999; 131:660-7.